Vitrakvi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance mutation, that are metastatic or for which surgical removal is too risky, that have no satisfactory alternative treatments, or that have grown following another treatment. Vitrakvi is sometimes prescribed to treat lung cancer. Vitrakvi is also referred to by its drug name, larotrectinib.
Vitrakvi is a member of a class of drugs called tyrosine kinase inhibitors. Vitrakvi is believed to work by inhibiting the activity of certain mutated kinases (proteins) that are involved in the proliferation of cancer cells, thus slowing the growth of tumors.
How do I take it?
Prescribing information states that Vitrakvi is taken orally as a capsule or liquid twice daily.
Vitrakvi should be taken exactly as prescribed by a physician.
The FDA-approved label for Vitrakvi lists common side effects including fatigue, nausea, dizziness, vomiting, cough, abnormal liver function, constipation, and diarrhea.
Rare but serious side effects listed for Vitrakvi include nerve damage, liver damage, and fetal harm.
For more details about this treatment, visit:
Vitrakvi (Larotrectinib) — Bayer
Larotrectinib (Oral Route) — Mayo Clinic